Previous 10 | Next 10 |
home / stock / clvly / clvly news
MELBOURNE, Australia, May 09, 2022 (GLOBE NEWSWIRE) -- A new potential therapy for the pigment loss disorder vitiligo will undergo further studies in North America this year. The drug afamelanotide – approved by US and European regulators for a rare light intolerance disorder –...
EXECUTIVE SUMMARY afamelanotide evaluated as safe in mild to moderate arterial ischaemic stroke (NIHSS 1–15, n=6) NIHSS 1 scores improved in five patients brain scans (MRI-FLAIR 2 ) in all patients show reduction of affected tissue strong functional recovery...
LONDON, April 29, 2022 (GLOBE NEWSWIRE) -- Dear shareholders, friends, Both from a professional viewpoint and as largest private holder, I have felt the urge to share my uncensored mind on the disproportionate decline in CLINUVEL’s value. Naturally, I experience chagrin...
Clinuvel Pharmaceuticals Limited (BIP) Q2 2022 Earnings Conference Call February 23, 2022 02:00 AM ET Company Participants Malcolm Bull - Head, IR Darren Keamy - CFO, Secretary Lachlan Hay - Global Director-Operations Conference Call Participants Verity Wai-Smith - Monsoon Communications Pres...
Clinuvel Pharmaceuticals (OTCPK:CLVLY) press release: 1H GAAP EPS of A$11.90c. Revenue of A$24.63M (+56.5% Y/Y). For further details see: Clinuvel Pharmaceuticals reports 1H results
MELBOURNE, Australia, Nov. 08, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its pharmaceutical development portfolio with NEURACTHEL ® , novel formulations of the melanocortin adrenocorticotropic hormone (ACTH). The Company has secured supply of ACTH with one of its strategic par...
SCENESSE ® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) MELBOURNE, Australia, March 24, 2021 (GLOBE NEWSWIRE) -- CLINUVEL has expanded its clinical program to evaluate the DNA reparative potential of afamelanotide in skin cells which have been da...
MELBOURNE, Australia, Oct. 28, 2020 (GLOBE NEWSWIRE) -- The drug afamelanotide will be used for the first time in patients with acute stroke. The study will evaluate the safety and efficacy of afamelanotide, developed by Australian company CLINUVEL, in arterial ischaemic stroke (AIS). The a...
MELBOURNE, Australia, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Xeroderma pigmentosum (XP) patient receives SCENESSE ® treatment Note to editors: CLINUVEL is releasing in-depth infographics and a video explaining the mechanisms of action in XP and the overall DNA repair process. For upd...
MELBOURNE, Australia, Sept. 10, 2020 (GLOBE NEWSWIRE) -- CLINUVEL PHARMACEUTICALS LTD today announced the progression of its drug SCENESSE ® (afamelanotide 16mg) to treat the disease xeroderma pigmentosum (XP). The aim of the development program is to confirm the drug’s ability...
News, Short Squeeze, Breakout and More Instantly...
Clinuvel Pharms Ltd S/Adr Company Name:
CLVLY Stock Symbol:
OTCMKTS Market:
DÜSSELDORF, Germany, March 28, 2024 (GLOBE NEWSWIRE) -- Pioneering biopharmaceutical company CLINUVEL yesterday hosted a wide-ranging market briefing discussing its novel drug SCENESSE ® (afamelanotide) and the future of photomedicine. Over 70 guests discussed the Company ...
MALIBU, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Leading biotech company CLINUVEL last week joined an intimate event bringing together California’s most prolific investors and philanthropists at the Malibu home of Lady Gaga and Michael Polansky. The event, hosted by Lady Gaga and M...
UV, HEV protection for individuals at high risk of photoageing and skin cancer MELBOURNE, Australia, March 01, 2023 (GLOBE NEWSWIRE) -- CLINUVEL (ASX: CUV) (Börse Frankfurt: UR9) (ADR Level 1: CLVLY) today launched CYACÊLLE, a next generation of polychromatic solar care...